Product
Flublok
Aliases
Flublok Quadrivalent
2 clinical trials
2 indications
Indication
InfluenzaIndication
HumanClinical trial
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of AgeStatus: Terminated, Estimated PCD: 2019-04-26
Clinical trial
Randomized Participant- and Investigator-Blinded Trial to Compare the Clinical Efficacy of Recombinant Influenza Vaccine to Standard Dose Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18-64 Years in the United StatesStatus: Terminated, Estimated PCD: 2023-12-31